Historique de carrière de Jessica Stitt
Anciens postes connus de Jessica Stitt
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Director of Finance/CFO | 01/03/2021 | 01/04/2022 |
| MYOKARDIA, INC. | Corporate Officer/Principal | 01/02/2020 | 01/01/2021 |
| THERAVANCE BIOPHARMA, INC. | Public Communications Contact | - | - |
Formation de Jessica Stitt
| St. Anselm College | Undergraduate Degree |
| Simmons School of Management | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 5 |
| Royaume-Uni | 2 |
Opérationnelle
| Director of Finance/CFO | 1 |
| Corporate Officer/Principal | 1 |
| Public Communications Contact | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| THERAVANCE BIOPHARMA, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Gyroscope Therapeutics Holdings Plc
 Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Gyroscope Therapeutics Holdings Plc engages in the development of gene therapy beyond rare diseases. It focuses on age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Bourse
- Insiders
- Jessica Stitt
- Expérience
